The 2026 Midterms Come Into Focus: What Is at Stake This November
The 2026 midterm elections will decide control of Congress this November, with the economy and cost of living shaping up as central issues for voters.
Summer 2026 Travel Trends: How Americans Are Vacationing Differently This Year
Wellness travel, slow travel and mindful getaways are reshaping how Americans vacation in summer 2026. Here are the lifestyle trends defining the season.
Wellness in 2026: Why Prevention and Personalization Are Reshaping Health
In 2026, prevention and personalization are reshaping how Americans approach health, with new focus on sleep, metabolic health and sustainable everyday habits.
The Fed, Inflation and Tariffs: What Is Really Driving the U.S. Economy This Week
The Federal Reserve decides on rates this week amid sticky inflation, tariff pressures and a resilient consumer. Here is what is really driving the U.S. economy.
NFL Training Camps Open Across the League: The Storylines That Will Shape 2026
All 32 teams are reporting for summer camp, and the earliest whistles have already blown. Here is what to watch as the road to the 2026 season begins.
Big Tech’s AI Bill Comes Due: Earnings Week Puts the Trade to the Test
Microsoft, Meta, Apple and Amazon all report this week, and Wall Street wants one question answered: is the enormous spending on AI starting to pay off?
Wall Street Braces for a Pivotal Week as the Fed Decision and Big Tech Earnings Collide
Stocks finished mixed to start the week as investors positioned for a Federal Reserve rate decision Wednesday and a wave of megacap earnings, while a semiconductor sell-off underscored how much is riding on the days ahead.
Kiniksa’s One-Drug Engine Just Beat Again — ARCALYST Revenue Up 55%, Guidance Raised
Kiniksa Pharmaceuticals beat on revenue and raised its full-year outlook, powered by a single blockbuster drug: ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis. The result showed a focused, cash-generative commercial engine still growing fast. On July 28, $KNSA — Kiniksa Pharmaceuticals — reported second-quarter results that beat expectations and lifted the company’s […]